Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASD-006
- Development stage
- Preclinical
- Lead developer
- ASDERA
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
ASD-006 is a small molecule chemical drug developed by Asdera LLC, currently in preclinical development. It is part of a family of derivatives based on alpha-cyclodextrin (αCD), designed to down-regulate endocytosis by scavenging serum phospholipids. The compound is being investigated for its potential to prevent or treat age-related diseases, including atherosclerosis, type 2 diabetes mellitus, nonalcoholic steatohepatitis (NASH), and viral diseases. The mechanism leverages the ability of αCD derivatives to modulate lipid metabolism and cellular uptake processes implicated in metabolic and cardiovascular disorders[1][3].
Beyond the preview
Go deeper on ASD-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASD-006.